Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04108026
Other study ID # IFCT-1802
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date October 14, 2020
Est. completion date October 2025

Study information

Verified date March 2024
Source Intergroupe Francophone de Cancerologie Thoracique
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Immunotherapeutic approaches targeting immune checkpoint proteins PD-1/PD-L1 have recently demonstrated clinical efficacy in several cancer types, and have changed the therapeutic landscape in metastatic melanoma or non-small cell lung cancer (NSCLC). The monoclonal anti-PD-1 antibody nivolumab has been registered by both FDA (Food and Drug Administration) and EMA (European Medicine Agency), for metastatic NSCLC patients, after failure of a prior platinum-based chemotherapy. The approval was based on the results of phase III clinical trials in metastatic NSCLC. But all the trials only enrolled patients with good general condition, PS (Performance Status) 0 or 1. However, the prevalence of poor PS patients at time of diagnosis is high in lung cancer patients. For patients with metastatic NSCLC and PS 3, there is no standard treatment except best supportive care, since all trials that accrued unselected PS 3 patients fail to prove any survival advantage, and most PS >3 patients die within 2 to 4 months from diagnosis. Indeed, these patients are currently excluded from clinical trials. Specific dedicated clinical trials and treatment guidelines for this patient population are urgently needed, taking into account for the high prevalence of such patients.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 50
Est. completion date October 2025
Est. primary completion date November 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Subjects must have signed and dated an IEC (Independent Ethic Committee) approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal subject care. Subjects must be willing and able to comply with scheduled visits, treatment schedule, and laboratory testing. 2. Histologically or cytologically-proven NSCLC (squamous or non-squamous). If the diagnosis is cytologically-proven, sufficient material is necessary with at least 100 tumor cells evaluated for PD-L1 IHC (Immunohistochemistry). 3. PD-L1 expression =25% of tumor cells as assessed by the local pathology laboratory using protocols validated. 4. Available tumor samples for centralized PD-L1 immunohistochemistry analysis. 5. No EGFR (Epidermal Growth Factor Receptor) mutation and no ALK(Anaplasic Lymphoma Kinase) gene rearrangement. 6. Stage IV (8th classification TNM) M1a or M1b or M1c. 7. ECOG (Eastern Cooperative Oncology Group) PS = 2 or 3 despite optimal symptomatic treatment. 8. Body weight >30kg 9. No prior systemic anticancer therapy (chemotherapy, immunotherapy including durvalumab, or EGFR or ALK inhibitors) given as primary therapy for advanced or metastatic disease. Neoadjuvant or adjuvant chemotherapy is not considered as chemotherapy for advanced or metastatic disease. 10. Limited field of radiation for palliation within 2 weeks of the first dose of durvalumab is allowed, provided the lung is not in the radiation field and irradiated lesion(s) cannot be used as target lesions. 11. Age 18-75 years. 12. Measurable tumor disease by CT per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. 13. Life expectancy > 8 weeks according to the investigator opinion. 14. Adequate biological functions: neutrophils = 1500/mm3 ; platelets = 75 000/mm3 ; Hemoglobin = 9 g/dL ; Creatinine Clearance > 40 mL/min , AST and ALT = 2,5 ULN unless liver metastases are present, AST (aspartate aminotransferase) and ALT (alanine aminotransferase) = 5 x ULN, serum bilirubin = 1.5 x ULN except for patients with proved, Gilbert syndrome (= 5 x ULN) or patients with hepatic metastases (= 3 x ULN). 15. Other investigations detailed in Section 5 must have been performed within the timelines indicated. 16. Protocol treatment is to begin within 7 days of patient inclusion. 17. Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply: - Women <50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy). - Women =50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy). 18. Females of childbearing potential who are sexually active with a nonsterilized male partner or men who are sexually active with women of childbearing potential must use a highly effective method of contraception prior the first dose of investigational product, and must agree to continue using such precautions for 90 days after the final dose of investigational product. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception. Exclusion Criteria: 1. Pure or combined SCLC. 2. Known HER2 (Human Epidermal Growth Factor Receptor), B-Raf, activating tumor mutations, or exon 14 c-MET splice mutations (mesenchymal-epithelial transition), or known ROS1 gene rearrangement. 3. Asymptomatic or symptomatic brain metastasis. 4. Carcinomatous meningitis. 5. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion: - Patients with vitiligo or alopecia - Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement - Any chronic skin condition that does not require systemic therapy - Patients without active disease in the last 5 years may be included but only after consultation with IFCT - Patients with celiac disease controlled by diet alone 6. Immunosuppressive treatment including systemic treatment with corticosteroids with greater dose than 10 mg prednisone equivalent daily, within 15 days before enrollment. Inhaled, nasal or topic corticosteroids are allowed. 7. History of allogenic organ transplantation. 8. Stage 4 (very severe, FEV1 (forced expiratory volume at one second) <30% predicted) chronic obstructive pulmonary disease (COPD) according to GOLD classification. 9. NYHA (New York Heart Association) class 4 chronic heart failure 10. Pre-existing interstitial lung. 11. History of another primary malignancy except for : - Malignancy treated with curative intent and with no known active disease =2 years before the first dose of IP (Investigational Product) and of low potential risk for recurrence - Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease - Adequately treated carcinoma in situ without evidence of residual disease Patients with a prostate adenocarcinoma history within the previous 5 years could be included in case of localized prostate cancer. 12. Living attenuated vaccine received within the 30 previous days. 13. Received any other experimental treatment or participation to any other therapeutic clinical trial. 14. Known allergy or hypersensitivity to any of the study drug or any of the study drug excipients. 15. Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable. 16. Major surgical procedure within 28 days prior to the first dose of IP or planned surgical procedure during treatment. 17. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs (Adverse Events) or compromise the ability of the patient to give written informed consent. 18. Active infection including tuberculosis, hepatitis B (known positive HBV surface antigen (HBsAg) result) and hepatitis C,. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA. History of active tuberculosis or evident primo-infection for which there is no record or evidence of an active anti-tuberculous treatment (please consult IFCT in case of doubt). 19. Patient with human immunodeficiency virus (positive HIV ½ antibodies) 20. Any condition that, in the opinion of investigator, could compromise the adherence to treatment and follow-up. 21. Mental illness or psychological condition, which in the opinion of investigator could compromise the expression of the informed consent. 22. No public health insurance.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Durvalumab
1500 mg IV every 4 weeks

Locations

Country Name City State
France Besançon - CHU Besançon
France Hôpital Ambroise Paré - Pneumologie Boulogne
France Caen - CHU Côte de Nacre Caen
France CH Colmar
France CHRU Grenoble Grenoble
France Centre Hospitalier - Pneumologie Le Mans
France CHRU de Lille Lille
France AP-HM Hopital Nord Marseille
France Montpellier - CHRU Montpellier
France GRH Mulhouse Sud-Alsace Mulhouse
France Nancy - Institut de Cancérologie de Lorraine Nancy
France Nantes - ICO Site René Gauducheau Nantes
France CHR d'Orléans La Source Orléans
France AP-HP Hopital Tenon - Pneumologie Paris
France Paris - APHP Bichat Paris
France Paris - Curie Paris
France Lyon - URCOT Pierre-Bénite
France CHU Strasbourg Strasbourg
France CHU Toulouse - Pneumologie Toulouse
France CHU Tours - Pneumologie Tours

Sponsors (1)

Lead Sponsor Collaborator
Intergroupe Francophone de Cancerologie Thoracique

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of patients experiencing Grade 3-5 Treatment Related Adverse Event at 8 weeks of durvalumab 8 weeks
Secondary Incidence, type and severity of adverse event The maximum grade will be summarized by frequency and proportion of total patients, by system organ class and NCI-CTC, Version 5.0 categories. From time of informed consent through treatment period (24 months) or up to 100 days post last dose of study treatment
Secondary Disease Control Rate Percentage of patients with objective response or stable disease according to RECIST 1.1 in the intent to treat population 8 weeks
Secondary Objective Response Rate according to BICR (Blinded Independent Central Review) and investigators Percentage of patients with objective response according to RECIST 1.1 in the intent to treat population 8 weeks (confirmed at 16 weeks)
Secondary Progression free survival Time between the date of durvalumab initiation and the first date of documented progression or death due to any cause, whichever occurs first. 6 and 12 months
Secondary Overall survival Time between the date of durvalumab initiation and the date of death due to any cause, whichever occurs first. 6 and 12 months
Secondary Performance status improvement rate Proportion of per-protocol patients whose PS during durvalumab treatment was improved from baseline From time of randomisation through treatment period (24 months)
Secondary Evaluate the Quality of life EORTC QLQ-C30 +LC13 (Qualify of Life Questionnaire C30 + Lung Cancer 13) questionnaire From time of randomisation through treatment period (24 months)
Secondary Centrally-assessed PD-L1 tumor expression Prognostic and predictive value Baseline only
Secondary Evaluate the Quality of life EQ-5D (EuroQol 5 Dimensions) questionnaire From time of randomisation through treatment period (24 months)
See also
  Status Clinical Trial Phase
Completed NCT02047344 - Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC Phase 2
Terminated NCT00766246 - Phase II Avastin Trial for Stage IIIB/IV NSCLC Phase 2
Active, not recruiting NCT04432207 - A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer Phase 1
Recruiting NCT05598853 - Intrathecal Double Checkpoint Inhibition Phase 1
Not yet recruiting NCT06117644 - The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC
Terminated NCT01348126 - Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer Phase 2/Phase 3
Completed NCT01086254 - SAR240550 in Combination With Gemcitabine/Cisplatin in Non-small Cell Lung Cancer Phase 2
Terminated NCT01798485 - A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC Phase 3
Recruiting NCT06348199 - A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer Phase 3
Not yet recruiting NCT06436144 - Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC Phase 2
Terminated NCT04289259 - Tumor Mutational Burden in Lung Cancer Patients
Active, not recruiting NCT05818449 - Improvement of Personalized Lung Cancer Care Through Digital Connection and Patient Participation (DigiNet) N/A
Completed NCT03526900 - Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis Phase 2
Not yet recruiting NCT06463665 - Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's of Choice Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer (VIRO-25) Phase 2
Completed NCT02176369 - Maintenance Low Dose Oral Navelbine In Patients With Non Small Cell Lung Cancer - MA.NI.LA Trial Phase 2
Terminated NCT03275597 - Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition Phase 1
Completed NCT02450539 - A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer Phase 2
Active, not recruiting NCT05055167 - Envafolimab as First-line Treatment of Aged Patients in Advanced NSCLC Phase 2
Not yet recruiting NCT03532698 - Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC)
Not yet recruiting NCT03543683 - Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC

External Links